Abstract
In the last years, several effective medications were introduced on the market, called disease modifying therapies, e.g. recombinant interferon ² (INF-²) and glatiramer acetate (GA), but they have a partial control on multiple sclerosis (MS). In 2006, a monoclonal humanized antibody (Natalizumab) that binds to ±4 subunit of integrins expressed on activated T cells surface showed a superio…